| Heading: |
Brain: Tumours |
| Question ID: |
1818987 |
| UIN: |
64594 |
| House: |
Commons |
| Date tabled: |
2025-07-02 |
| Asking Member ID: |
4872 |
| Asking Member display name: |
David Simmonds
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
David Simmonds
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) the Medicines and Healthcare products Regulatory Agency and (b) the National institute for Health and Care Excellence on access to innovative treatment for pati |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-10 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department is committed to ensuring that all patients, including those with brain tumours, have access to cutting-edge clinical trials and innovative, lifesaving treatments. As such, officials meet regularly with the Medicines and Healthcare products ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |